By David Sanders, Washington Examiner – May 13, 2022
Congress and the administration have a duty to prepare for the long haul and make changes to increase domestic production of our medical supply chain. The United States remains woefully unprepared to respond to supply chain shocks that rattled the country in the early days of COVID-19 and continue to leave patients vulnerable.
It’s more important than ever to work across the aisle to support policy that spurs manufacturing in the U.S. and U.S. allies. Earlier this year, Sens. Tina Smith (D-MN) and Tom Cotton (R-AR) and Reps. Angie Craig (D-MN) and Markwayne Mullin (R-OK) introduced the American Made Pharmaceuticals Act. This bipartisan, bicameral legislation will secure our supply chain and catalyze American manufacturing jobs by providing a variety of tools that allow for the preference of generics, biosimilars, and critical medicines made here. One of those tools is a meaningful step to secure and cure our medical supply chain — allowing Medicare to recognize and reward high-quality products made in America and in allied countries.